Skip to main content
. Author manuscript; available in PMC: 2013 Aug 23.
Published in final edited form as: Cancer J. 2012 Mar-Apr;18(2):153–159.

Table 1.

Selected Ipilimumab Combination Clinical Trials for Patients with Melanoma (Source: www.clinicaltrials.gov)

Agent(s)
used in
Combination
with
Ipilimumab		 Patient Population Study ID Phase Status
Vemurafenib Unresectable/Metastatic NCT01400451 I Not yet
accruing
Bevacizumab Unresectable/Metastatic NCT00790010 I Accruing
BMS-936558

(PD-1
Inhibitor)		 Unresectable/Metastatic NCT01024231 I Accruing
Temozolomide,
cisplatin,
interferon
alpha-2b,
Interleukin-2
(IL-2)		 Unresectable/Metastatic,
no prior chemotherapy.		 NCT01409174 I/II Not yet accruing
Palliative
Radiation		 Metastatic melanoma,
failed or intolerant to at
least one prior line of
therapy		 NCT01449279 Pilot
Study		 Accruing
Granulocyte
Macrophage-
Colony
Stimulating
Factor		 Unresectable/Metastatic NCT01363206 II Accruing
Temozolomide Unresectable/Metastatic,
no prior chemotherapy
or targeted therapy		 NCT01119508 II Ongoing but not accruing